Alzheimer�s Digital Therapeutic to Unlock the Power of Music Therapy

TORONTO--(BUSINESS WIRE)--12.7 million Americans aged 65 and older are projected to have Alzheimer�s dementia by 2050. LUCID and JT are now partnering on the development of a prescription digital therapeutic for Alzheimer�s disease.

Alzheimer�s is more than just memory loss � neuropsychiatric symptoms can include anxiety, aggression and personality changes. These symptoms aren�t just heartbreaking, they�re promoting the burnout of caregivers. Treatment is more necessary than ever.

�People living with Alzheimer�s deserve dignity in this stage of their life,� stated Zach McMahon, CEO and co-founder of LUCID. �They deserve a treatment that is both effective and can enhance quality of life for them and their caregivers.�

Earlier this year, LUCID�s first randomized controlled clinical trial demonstrated clinical evidence in the reduction of acute anxiety within adults with moderate anxiety. With the support of JT, LUCID will translate their data-driven clinical insights into the development of a digital therapeutic to reduce agitation and anxiety in dementia care, initially with Alzheimer�s.

�Music interventions can ease these psychiatric symptoms and spark joy,� McMahon said. �We�re committed to delivering new care paradigms in an evidence-based way.�

Now, with funding from JT, LUCID will conduct research and development of the digital therapeutic that will be known as LUC-101. Sheridan College�s Centre for Elder Research is also involved in the development of LUC-101 through a Natural Sciences and Engineering Research Council of Canada (NSERC) initiative to support gerontological research and design.

LUCID will take a leadership position to deliver the power of music as medicine to patients and caregivers globally. With LUC-101, LUCID strives to deliver the benefits of personalized music therapy for Alzheimer�s whilst lowering the overall cost and barrier to entry through AI technology and cloud-enabled applications.

About LUCID

LUCID develops therapeutic music experiences for mental health. By unlocking the power of neuroscience and machine learning, LUCID�s AI curates music experiences that are optimized for specific emotional outcomes. They aim to provide personalized, evidence-based, and accessible solutions in mental health care. LUCID is working towards the clinical validation of music as medicine.

LUCID�s latest clinical trial is The Effect of Music & Auditory Beat Stimulation on Anxiety. For more information, please visit www.thelucidproject.ca.

About JT

JT, Japan Tobacco Inc., has a pharmaceutical business which focuses on research and development, manufacturing and sales of prescription drugs. For more information, please visit https://www.jt.com/about/division/pharma/index.html.

Contacts

Kendall Saretsky

kendall.saretsky@mindmeldpr.com